Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nisin in Oral Cavity Squamous Cell Carcinoma
NCT06097468Phase 2Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Feb 2024
- Primary completion
- Mar 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of nisin in oral cavity squamous cell carcinoma (OCSCC) (2 arms), sponsored by University of California, San Francisco. Primary endpoints: Proportion of participants with dose limiting toxicities at 6 months, Maximum Tolerated Dose / Recommended Phase II Dose at 4 weeks and 1 more. Started Feb 2024; status: recruiting.
02
Drugs
nisin
03
Conditions
oral cavity squamous cell carcinoma (OCSCC)
Beyond the preview
Go deeper on NCT06097468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06097468.